 Anavex will present results from its phase 2b3 trial for blarcamesine for Alzheimers disease at the CTAD conference in San Francisco on December 1st. A past trial suggests that Anavexs blarcamesine modifies mild Alzheimers disease in some patients at 148 weeks. 